Mizuho upgraded shares of Senseonics (NYSE:SENS – Free Report) to a strong-buy rating in a report published on Wednesday,Zacks.com reports.
Several other research analysts have also issued reports on SENS. StockNews.com started coverage on shares of Senseonics in a research report on Thursday, December 26th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Wednesday, March 5th.
Check Out Our Latest Stock Analysis on Senseonics
Senseonics Stock Performance
Senseonics (NYSE:SENS – Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same quarter in the previous year, the firm earned ($0.07) EPS. Equities research analysts anticipate that Senseonics will post -0.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in shares of Senseonics in the fourth quarter worth approximately $26,000. HighTower Advisors LLC purchased a new stake in Senseonics in the fourth quarter worth approximately $32,000. Two Sigma Investments LP purchased a new stake in Senseonics during the 4th quarter valued at $36,000. FMR LLC raised its stake in Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after buying an additional 167,970 shares during the last quarter. Finally, Ridgecrest Wealth Partners LLC purchased a new position in shares of Senseonics in the 4th quarter worth $60,000. 12.36% of the stock is owned by institutional investors.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
Recommended Stories
- Five stocks we like better than Senseonics
- The Significance of Brokerage Rankings in Stock Selection
- JPMorgan is a Buy, if You Can Handle The Volatility
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- United States Steel’s Crash: An Unmissable Buying Opportunity
- Business Services Stocks Investing
- Rocket Lab Stock: Weathering the Storm, Time for a Comeback?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.